Photo taken from Oncology Brothers/X
Jun 4, 2024, 03:08
ASCO24 Day 3 Highlights by The Oncology Brothers
The Oncology Brothers shared on X:
“1. DB06 TDxD HR+ metastatic breast cancer (mBC)
2. TransMet Liver transplant in metastatic colorectal cancer (mCRC)
3. Collision Surgery/Ablation in mCRC
4. ESOPEC (UpperGI)
5. LAURA Consolidation (mNSCLC)
6. ADRIATIC Durva (LS-SCLC)
7. ReachPC: Palliative Oncology
8. NADINA (Melanoma)
1. DestinyBreast06:
- Phase III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
- Majority of HR+ (85%) in this category
- PFS 13.2 vs 8.1 mos (HR 0.62)
- AEs: ILD, Fatigue, and Nausea
- Should I even test for Her2?
2. TransMet:
- Chemo plus Liver transplant vs Chemo in metastatic liver confined CRC
- mFU of 59 months, PFS 57% vs 13% (HR: 0.37)
- OS: 73% vs 9% (HR: 0.16)
- Importance of Multi-D for liver confined disease
3. COLLISION:
- Surgery vs Ablation in Liver confined/resectable metastatic CRC
- No OS difference with thermal ablation or surgery for small Mets
- Medium size 14mm and 2 lesions
- Importance of Multi-D but in the right patient, they can stay close to home .
4. ESOPEC:
- Phase III, perioperative FLOT vs NeoAdj Chemoradiation in adeno-esophageal carcinoma:
- pCR FLOT (17% vs 10%)
- Much pCR than original CROSS (23%)
- 3 yearr OS: 57.4% vs 50.7% (mOS: 66 months vs 37months)
- FLOT better in all subgroups (benefit limited in N0).
- What about CM577?
5. LAURA:
- Phase III, Indefinite Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
- New SoC
- Increase of PFS with Osi, 39.1 months vs 5.6 months (HR 0.16)
- OS Pending –
- 2 year PFS: 65% vs 13%
- High cross over/received osi at progression
- ≥Gr 3 AEs: 35% vs 12%
6. ADRIATIC:
- Phase III, durvalumab ± Tremi for 2 years after concurrent ChemoXRT limited stage small cell lung cancer
- New SoC
- Increase of OS with durva 55.9months vs 33.4 months (HR 0.73)
- Increase of PFS (HR: 0.76)
- Increase of AEs with Durvalumab
7. ReachPC:
- Role of Palliative Oncology using teleheath in Lung Cancer, n=1250
- Collaboration with palliative oncology is critical
- No QoL difference seen via telehealth or in person
- Similar satisfaction by both means
8. NADINA:
- Phase III, n = 432, NeoAdj Ipi/Nivo vs. Adj Nivo in Stage III melanoma
- New SoC
- 1 year EFS: 83.7% vs 57.2%
- Difference in restricted survival was 8 months (HR: 0.32)
- 59% major path response
- ≥Gr 3 AEs 29.7% with Ipi Nivo”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46